efficacy

The efficacy and safety of direct-acting antiviral agents in patients with chronic HCV infection and UGT1A1*28 polymorphism

Objective. To determine the efficacy and safety of direct-acting antiviral agents (DAA) in patients with chronic HCV infection and UGT1A1*28 polymorphism. Materials and Methods. An open-label, non-randomized, observational study to assess efficacy and safety of DAA in patients (n = 143) with chronic hepatitis C (CHC) and liver cirrhosis and UGT1A1*28 polymorphism was performed. A total of 139 patients with chronic HCV infection were included in the efficacy analysis (absence of HCV RNA in blood by PCR) by the rate of sustained virologic response at week 12 (SVR12).

Safety and efficacy of nemonoxacin versus levofloxacin in the treatment of community-acquired pneumonia: results of phase III, multicenter, randomized, double-blind, active-controlled, non-inferiority trial

Objective. To evaluate the efficacy and safety of a step-down strategy from intravenous to oral nemonoxacin versus a step-down strategy from intravenous to oral levofloxacin in the treatment of patients with community-acquired pneumonia. Materials and Methods. This was a phase III randomized, controlled, double-blind, double-dummy, parallel groups (2 groups), multicenter trial to evaluate the efficacy and safety of intravenous and oral nemonoxacin at a daily dose of 500 mg versus levofloxacin (Tavanic®) at a daily dose of 500 mg in the treatment of adult patients with community-acquired pneumonia.

Use of Antimicrobial Agents in Elderly Patients

This article describes the factors contributing reduced efficacy of antimicrobial agents in elderly patients, as well as the factors and mechanisms compromising safety of this drug class. Specific aspects of the administration of different …

Efficacy and Safety of Azithromycin in the Treatment of Sexually Transmitted Diseases

This paper considers safety issues associated with medical therapy of sexually transmitted diseases (STDs). Data supporting safety of azithromycin as part of treatment regimens for infections due to chlamydia and mycoplasma are provided. Possible …

Levofloxacin in the Treatment of Community-Acquired Pneumonia: 20-Year Successful Clinical Experience

According to international post-marketing trials, levofloxacin now belongs to the antimicrobial agents being in a great demand in clinical practice. One of the main indications for its use is community-acquired pneumonia (CAP). This review article is …

Ciprofloxacin in Current Clinical Practice

Ciprofloxacin is the most known member of second generation quinolones, which is more active against gram-negative microorganisms and has broad antimicrobial spectrum compared to first generation quinolones. This article presents the main indications …

Pharmacotherapy of Vulvovaginal Candidiasis According to Pharmacoepidemiology Data and Evidence-Based Medicine

Approximately 75% of women experience at least one episode of acute vulvovaginal candidiasis during their life. In the 1980-90s, almost two-fold increase in fungal vaginitis was observed with increase in number of cases caused by non-albicans strains …

Use of Carbapenems in Clinical Practice: When, Which and How Long?

Carpabenems (imipenem, meropenem, ertapenem) are currently one of the antibiotic classes that exhibit the broadest spectrum of activity and characterized by the low resistance rates of clinically significant pathogens. This article is an attempt to …

Assessment of Mortality Rate and Efficacy of Antimicrobial Therapy in Patients with Community-Acquired Pneumonia in Sverdlovsk Region

Efficacy of regional standard of care «CommunityAcquired Pneumonia» and Sverdlovsk regional healthcare program «Intensive Care» were assessed. This paper presents results of retrospective analysis of ICU hospitalizations for severe community-acquired …